SCHEMBL21747422

SCHEMBL21747422

Cc1ccc(-c2cccn2C2(C(=O)O)CCCC2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
EGLN1 Q9GZT9 6/20 0.36
CYP2C19 P33261 1/20 0.33
ITGB1 P05556 2/20 0.33
ITGA4 P13612 2/20 0.33
KDM4E B2RXH2 3/20 0.33
ALOX15 P16050 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
APEX1 P27695 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
AKR1C1 Q04828 1/20 0.33
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21747303 0.88 ALDH1A1 (0.40) ALDH1A1EGLN1KDM4EMEN1KMT2A
SCHEMBL21747254 0.87 ALDH1A1 (0.39) ALDH1A1EGLN1KDM4EMEN1KMT2A
SCHEMBL21747351 0.86 ERAP1 (0.36) ALDH1A1EGLN1KDM4EL3MBTL1SMN1; SMN2
SCHEMBL21747407 0.86 HSD11B1 (0.36) ALDH1A1EGLN1CYP2C19KDM4EPOLB
SCHEMBL21747395 0.85 EGLN1 (0.37) ALDH1A1EGLN1ITGB1ITGA4KDM4E
SCHEMBL21747417 0.85 EGLN1 (0.37) ALDH1A1EGLN1KDM4EMEN1HPGD
SCHEMBL21747397 0.85 FAAH (0.40) ALDH1A1CYP2C19KDM4EHSD17B10MEN1
SCHEMBL21747277 0.84 HSD11B1 (0.38) EGLN1CYP2C19KDM4EPOLB
SCHEMBL21747387 0.84 ERAP1 (0.38) ALDH1A1EGLN1KDM4EL3MBTL1
SCHEMBL21747377 0.84 FAAH (0.42) ALDH1A1KDM4EHSD17B10MEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970495-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-30 US disclosed
US-11945817-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-02 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 US disclosed
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2021-08-19 US disclosed
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2021-08-19 US disclosed
CN-113004271-A Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-06-22 CN disclosed
US-11021478-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2021-06-01 US disclosed
US-11021478-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2021-06-01 US disclosed
CN-108484598-B Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-03-02 CN disclosed
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2020-05-28 US disclosed
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2020-05-28 US disclosed
EP-3613742-A1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE Kind Pharmaceutical (CN) 2020-02-26 EP disclosed
EP-3613742-A1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE Kind Pharmaceutical (CN) 2020-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 ALDH1A1 1770/4885EGLN1 4427/4885CYP2C19 40/4885
US-11021478-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 ALDH1A1 1770/4885EGLN1 4427/4885CYP2C19 40/4885
US-11970495-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 ALDH1A1 1770/4885EGLN1 4427/4885CYP2C19 40/4885
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 ALDH1A1 1770/4885EGLN1 4427/4885CYP2C19 40/4885
US-11945817-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 ALDH1A1 1770/4885EGLN1 4427/4885CYP2C19 40/4885
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 ALDH1A1 1770/4885EGLN1 4427/4885CYP2C19 40/4885
US-11655249-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 ALDH1A1 1770/4885EGLN1 4427/4885CYP2C19 40/4885
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 ALDH1A1 1770/4885EGLN1 4427/4885CYP2C19 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.